Skip to main
TYRA

Tyra Biosciences (TYRA) Stock Forecast & Price Target

Tyra Biosciences (TYRA) Analyst Ratings

Based on 11 analyst ratings
Strong Buy
Strong Buy 64%
Buy 36%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tyra Biosciences is poised for success with its cutting-edge precision medicine platform, SNAP, and promising product pipeline targeting FGFR-driven conditions. With strong potential for dabogratinib's success in the market and the company's in-house drug design capabilities, Tyra Biosciences could potentially become a leading player in the biotech industry.

Bears say

Tyra Biosciences is a clinical-stage biotechnology company that has potential drugs in its pipeline for targeted oncology and genetically defined conditions, but has yet to demonstrate best-in-class efficacy and safety that would validate its oral treatment option as an alternative for patients. The company's financial performance is currently uncertain and highly dependent on the results of their upcoming drug trials. However, if successful, Tyra Biosciences could generate significant upside and value in the urology and skeletal dysplasia markets.

Tyra Biosciences (TYRA) has been analyzed by 11 analysts, with a consensus rating of Strong Buy. 64% of analysts recommend a Strong Buy, 36% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tyra Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tyra Biosciences (TYRA) Forecast

Analysts have given Tyra Biosciences (TYRA) a Strong Buy based on their latest research and market trends.

According to 11 analysts, Tyra Biosciences (TYRA) has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tyra Biosciences (TYRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.